Known targets — ChEMBL curated mechanism
CACNA1CCACNA1DCACNA1FCACNA1SDRD2HTR1BHTR1DHTR1F
The experimentally established mechanism targets of Malic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Malic Acid SCHEMBL3051504 | 0.94 | ADRB2 (0.55) | ADRB2ADRB1 | |
| SCHEMBL1040734 | 0.94 | ADRB2 (0.65) | ADRB2ADRB1 | |
| Hydrochloric Acid SCHEMBL3045932 | 0.93 | ADRB2 (0.64) | ADRB2ADRB1 | |
| Bromide SCHEMBL3058759 | 0.93 | ADRB2 (0.64) | ADRB2ADRB1 | |
| Malic Acid SCHEMBL3040702 | 0.93 | ADRB2 (0.58) | ADRB2ADRB1 | |
| Maleic Acid SCHEMBL3055528 | 0.92 | ADRB2 (0.59) | ADRB2ADRB1 | |
| Fumaric Acid SCHEMBL3055532 | 0.92 | ADRB2 (0.59) | ADRB2ADRB1 | |
| Malic Acid SCHEMBL3048507 | 0.90 | ADRB2 (0.52) | ADRB2ADRB1 | |
| SCHEMBL1038740 | 0.87 | ADRB2 (0.64) | ADRB2ADRB1 | |
| SCHEMBL1041706 | 0.87 | ADRB2 (0.59) | ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222336-A1 | SINGLE ENANTIOMER BETA-AGONISTS, METHODS FOR THE PRODUCTION THEREOF AND THE USE THEREOF AS MEDICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222336-A1 | SINGLE ENANTIOMER BETA-AGONISTS, METHODS FOR THE PRODUCTION THEREOF AND THE USE THEREOF AS MEDICATION | ADRB1, ADRA1A, ADRB2 | ADRB2 3/4885ADRB1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.